Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Aug 1;100(3):558–564. doi: 10.1172/JCI119565

Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice.

N W Boonmark 1, X J Lou 1, Z J Yang 1, K Schwartz 1, J L Zhang 1, E M Rubin 1, R M Lawn 1
PMCID: PMC508222  PMID: 9239402

Abstract

Lipoprotein(a) contributes to the development of atherosclerosis through the binding of its plasminogen-like apolipoprotein(a) component to fibrin and other plasminogen substrates. Apolipoprotein(a) contains a major lysine binding site in one of its kringle domains. Destruction of this site by mutagenesis greatly reduces the binding of apolipoprotein(a) to lysine and fibrin. Transgenic mice expressing this mutant form of apolipoprotein(a) as well as mice expressing wild-type apolipoprotein(a) have been created in an inbred mouse strain. The wild-type apolipoprotein(a) transgenic mice have a fivefold increase in the development of lipid lesions, as well as a large increase in the focal deposition of apolipoprotein(a) in the aorta, compared with the lysine binding site mutant strain and to nontransgenic littermates. The results demonstrate the key role of this lysine binding site in the pathogenic activity of apolipoprotein(a) in a murine model system.

Full Text

The Full Text of this article is available as a PDF (4.6 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armstrong V. W., Harrach B., Robenek H., Helmhold M., Walli A. K., Seidel D. Heterogeneity of human lipoprotein Lp[a]: cytochemical and biochemical studies on the interaction of two Lp[a] species with the LDL receptor. J Lipid Res. 1990 Mar;31(3):429–441. [PubMed] [Google Scholar]
  2. Assmann G., Schulte H., von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996 Jun 1;77(14):1179–1184. doi: 10.1016/s0002-9149(96)00159-2. [DOI] [PubMed] [Google Scholar]
  3. Bas Leerink C., Duif P. F., Gimpel J. A., Kortlandt W., Bouma B. N., van Rijn H. J. Lysine-binding heterogeneity of Lp(a): consequences for fibrin binding and inhibition of plasminogen activation. Thromb Haemost. 1992 Aug 3;68(2):185–188. [PubMed] [Google Scholar]
  4. Bostom A. G., Cupples L. A., Jenner J. L., Ordovas J. M., Seman L. J., Wilson P. W., Schaefer E. J., Castelli W. P. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA. 1996 Aug 21;276(7):544–548. doi: 10.1001/jama.1996.03540070040028. [DOI] [PubMed] [Google Scholar]
  5. Callow M. J., Stoltzfus L. J., Lawn R. M., Rubin E. M. Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2130–2134. doi: 10.1073/pnas.91.6.2130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Callow M. J., Verstuyft J., Tangirala R., Palinski W., Rubin E. M. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). J Clin Invest. 1995 Sep;96(3):1639–1646. doi: 10.1172/JCI118203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chiesa G., Hobbs H. H., Koschinsky M. L., Lawn R. M., Maika S. D., Hammer R. E. Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a). J Biol Chem. 1992 Dec 5;267(34):24369–24374. [PubMed] [Google Scholar]
  8. Edelberg J. M., Gonzalez-Gronow M., Pizzo S. V. Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. Thromb Res. 1990 Jan 1;57(1):155–162. doi: 10.1016/0049-3848(90)90203-o. [DOI] [PubMed] [Google Scholar]
  9. Ernst A., Helmhold M., Brunner C., Pethö-Schramm A., Armstrong V. W., Müller H. J. Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). J Biol Chem. 1995 Mar 17;270(11):6227–6234. doi: 10.1074/jbc.270.11.6227. [DOI] [PubMed] [Google Scholar]
  10. Ferguson J. J. American College of Cardiology 45th Annual Scientific Session, Orlando, Florida, March 24 to 27, 1996. Circulation. 1996 Jul 1;94(1):1–5. doi: 10.1161/01.cir.94.1.1. [DOI] [PubMed] [Google Scholar]
  11. Gonzalez-Gronow M., Edelberg J. M., Pizzo S. V. Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein a compete for the same site. Biochemistry. 1989 Mar 21;28(6):2374–2377. doi: 10.1021/bi00432a005. [DOI] [PubMed] [Google Scholar]
  12. Grainger D. J., Kemp P. R., Liu A. C., Lawn R. M., Metcalfe J. C. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature. 1994 Aug 11;370(6489):460–462. doi: 10.1038/370460a0. [DOI] [PubMed] [Google Scholar]
  13. Grainger D. J., Kemp P. R., Metcalfe J. C., Liu A. C., Lawn R. M., Williams N. R., Grace A. A., Schofield P. M., Chauhan A. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat Med. 1995 Jan;1(1):74–79. doi: 10.1038/nm0195-74. [DOI] [PubMed] [Google Scholar]
  14. Grainger D. J., Kirschenlohr H. L., Metcalfe J. C., Weissberg P. L., Wade D. P., Lawn R. M. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993 Jun 11;260(5114):1655–1658. doi: 10.1126/science.8503012. [DOI] [PubMed] [Google Scholar]
  15. Guevara J., Jr, Jan A. Y., Knapp R., Tulinsky A., Morrisett J. D. Comparison of ligand-binding sites of modeled apo[a] kringle-like sequences in human lipoprotein[a]. Arterioscler Thromb. 1993 May;13(5):758–770. doi: 10.1161/01.atv.13.5.758. [DOI] [PubMed] [Google Scholar]
  16. Hajjar K. A., Gavish D., Breslow J. L., Nachman R. L. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989 May 25;339(6222):303–305. doi: 10.1038/339303a0. [DOI] [PubMed] [Google Scholar]
  17. Harpel P. C., Chang V. T., Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10193–10197. doi: 10.1073/pnas.89.21.10193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Harpel P. C., Gordon B. R., Parker T. S. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci U S A. 1989 May;86(10):3847–3851. doi: 10.1073/pnas.86.10.3847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hoover-Plow J. L., Boonmark N., Skocir P., Lawn R., Plow E. F. A quantitative immunoassay for the lysine-binding function of lipoprotein(a). Application to recombinant apo(a) and lipoprotein(a) in plasma. Arterioscler Thromb Vasc Biol. 1996 May;16(5):656–664. doi: 10.1161/01.atv.16.5.656. [DOI] [PubMed] [Google Scholar]
  20. Klezovitch O., Edelstein C., Scanu A. M. Evidence that the fibrinogen binding domain of Apo(a) is outside the lysine binding site of kringle IV-10: a study involving naturally occurring lysine binding defective lipoprotein(a) phenotypes. J Clin Invest. 1996 Jul 1;98(1):185–191. doi: 10.1172/JCI118765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Klezovitch O., Scanu A. M. Lys and fibrinogen binding of wild-type (Trp72) and mutant (Arg72) human apo(a) kringle IV-10 expressed in E coli and CHO cells. Arterioscler Thromb Vasc Biol. 1996 Mar;16(3):392–398. doi: 10.1161/01.atv.16.3.392. [DOI] [PubMed] [Google Scholar]
  22. Knight B. L., Perombelon Y. F., Soutar A. K., Wade D. P., Seed M. Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects. Atherosclerosis. 1991 Apr;87(2-3):227–237. doi: 10.1016/0021-9150(91)90025-x. [DOI] [PubMed] [Google Scholar]
  23. Kojima S., Harpel P. C., Rifkin D. B. Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol. 1991 Jun;113(6):1439–1445. doi: 10.1083/jcb.113.6.1439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Lackner C., Cohen J. C., Hobbs H. H. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet. 1993 Jul;2(7):933–940. doi: 10.1093/hmg/2.7.933. [DOI] [PubMed] [Google Scholar]
  25. Lawn R. M., Pearle A. D., Kunz L. L., Rubin E. M., Reckless J., Metcalfe J. C., Grainger D. J. Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. J Biol Chem. 1996 Dec 6;271(49):31367–31371. doi: 10.1074/jbc.271.49.31367. [DOI] [PubMed] [Google Scholar]
  26. Lawn R. M., Wade D. P., Hammer R. E., Chiesa G., Verstuyft J. G., Rubin E. M. Atherogenesis in transgenic mice expressing human apolipoprotein(a) Nature. 1992 Dec 17;360(6405):670–672. doi: 10.1038/360670a0. [DOI] [PubMed] [Google Scholar]
  27. Linton M. F., Farese R. V., Jr, Chiesa G., Grass D. S., Chin P., Hammer R. E., Hobbs H. H., Young S. G. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J Clin Invest. 1993 Dec;92(6):3029–3037. doi: 10.1172/JCI116927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Liu A. C., Lawn R. M., Verstuyft J. G., Rubin E. M. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice. J Lipid Res. 1994 Dec;35(12):2263–2267. [PubMed] [Google Scholar]
  29. LoGrasso P. V., Cornell-Kennon S., Boettcher B. R. Cloning, expression, and characterization of human apolipoprotein(a) kringle IV37. J Biol Chem. 1994 Aug 26;269(34):21820–21827. [PubMed] [Google Scholar]
  30. Loscalzo J., Weinfeld M., Fless G. M., Scanu A. M. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis. 1990 Mar-Apr;10(2):240–245. doi: 10.1161/01.atv.10.2.240. [DOI] [PubMed] [Google Scholar]
  31. Mancini F. P., Newland D. L., Mooser V., Murata J., Marcovina S., Young S. G., Hammer R. E., Sanan D. A., Hobbs H. H. Relative contributions of apolipoprotein(a) and apolipoprotein-B to the development of fatty lesions in the proximal aorta of mice. Arterioscler Thromb Vasc Biol. 1995 Nov;15(11):1911–1916. doi: 10.1161/01.atv.15.11.1911. [DOI] [PubMed] [Google Scholar]
  32. McCance S. G., Menhart N., Castellino F. J. Amino acid residues of the kringle-4 and kringle-5 domains of human plasminogen that stabilize their interactions with omega-amino acid ligands. J Biol Chem. 1994 Dec 23;269(51):32405–32410. [PubMed] [Google Scholar]
  33. McLean J. W., Tomlinson J. E., Kuang W. J., Eaton D. L., Chen E. Y., Fless G. M., Scanu A. M., Lawn R. M. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987 Nov 12;330(6144):132–137. doi: 10.1038/330132a0. [DOI] [PubMed] [Google Scholar]
  34. Miles L. A., Fless G. M., Levin E. G., Scanu A. M., Plow E. F. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 1989 May 25;339(6222):301–303. doi: 10.1038/339301a0. [DOI] [PubMed] [Google Scholar]
  35. Miles L. A., Plow E. F. Lp(a): an interloper into the fibrinolytic system? Thromb Haemost. 1990 Jun 28;63(3):331–335. [PubMed] [Google Scholar]
  36. Moliterno D. J., Lange R. A., Meidell R. S., Willard J. E., Leffert C. C., Gerard R. D., Boerwinkle E., Hobbs H. H., Hillis L. D. Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction. Circulation. 1993 Sep;88(3):935–940. doi: 10.1161/01.cir.88.3.935. [DOI] [PubMed] [Google Scholar]
  37. Mortimer B. C., Redgrave T. G., Spangler E. A., Verstuyft J. G., Rubin E. M. Effect of human apoE4 on the clearance of chylomicron-like lipid emulsions and atherogenesis in transgenic mice. Arterioscler Thromb. 1994 Oct;14(10):1542–1552. doi: 10.1161/01.atv.14.10.1542. [DOI] [PubMed] [Google Scholar]
  38. Mosedale D. E., Metcalfe J. C., Grainger D. J. Optimization of immunofluorescence methods by quantitative image analysis. J Histochem Cytochem. 1996 Sep;44(9):1043–1050. doi: 10.1177/44.9.8773570. [DOI] [PubMed] [Google Scholar]
  39. Mulichak A. M., Tulinsky A., Ravichandran K. G. Crystal and molecular structure of human plasminogen kringle 4 refined at 1.9-A resolution. Biochemistry. 1991 Oct 29;30(43):10576–10588. doi: 10.1021/bi00107a029. [DOI] [PubMed] [Google Scholar]
  40. Nielsen P. R., Einer-Jensen K., Holtet T. L., Andersen B. D., Poulsen F. M., Thøgersen H. C. Protein-ligand interactions in the lysine-binding site of plasminogen kringle 4 are different in crystal and solution. Electrostatic interactions studied by site-directed mutagenesis exclude Lys35 as an important acceptor in solution. Biochemistry. 1993 Dec 7;32(48):13019–13025. doi: 10.1021/bi00211a010. [DOI] [PubMed] [Google Scholar]
  41. Palabrica T. M., Liu A. C., Aronovitz M. J., Furie B., Lawn R. M., Furie B. C. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med. 1995 Mar;1(3):256–259. doi: 10.1038/nm0395-256. [DOI] [PubMed] [Google Scholar]
  42. Rader D. J., Mann W. A., Cain W., Kraft H. G., Usher D., Zech L. A., Hoeg J. M., Davignon J., Lupien P., Grossman M. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest. 1995 Mar;95(3):1403–1408. doi: 10.1172/JCI117794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Rouy D., Grailhe P., Nigon F., Chapman J., Anglés-Cano E. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu. Arterioscler Thromb. 1991 May-Jun;11(3):629–638. doi: 10.1161/01.atv.11.3.629. [DOI] [PubMed] [Google Scholar]
  44. Rubin E. M., Krauss R. M., Spangler E. A., Verstuyft J. G., Clift S. M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991 Sep 19;353(6341):265–267. doi: 10.1038/353265a0. [DOI] [PubMed] [Google Scholar]
  45. Scanu A. M., Fless G. M. Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest. 1990 Jun;85(6):1709–1715. doi: 10.1172/JCI114625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Scanu A. M., Pfaffinger D., Lee J. C., Hinman J. A single point mutation (Trp72-->Arg) in human apo(a) kringle 4-37 associated with a lysine binding defect in Lp(a). Biochim Biophys Acta. 1994 Oct 21;1227(1-2):41–45. doi: 10.1016/0925-4439(94)90104-x. [DOI] [PubMed] [Google Scholar]
  47. Trieu V. N., Zioncheck T. F., Lawn R. M., McConathy W. J. Interaction of apolipoprotein(a) with apolipoprotein B-containing lipoproteins. J Biol Chem. 1991 Mar 25;266(9):5480–5485. [PubMed] [Google Scholar]
  48. Utermann G. The mysteries of lipoprotein(a). Science. 1989 Nov 17;246(4932):904–910. doi: 10.1126/science.2530631. [DOI] [PubMed] [Google Scholar]
  49. Widom R. L., Ladias J. A., Kouidou S., Karathanasis S. K. Synergistic interactions between transcription factors control expression of the apolipoprotein AI gene in liver cells. Mol Cell Biol. 1991 Feb;11(2):677–687. doi: 10.1128/mcb.11.2.677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Williams J. K., Bellinger D. A., Nichols T. C., Griggs T. R., Bumol T. F., Fouts R. L., Clarkson T. B. Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of lipoprotein(a). Arterioscler Thromb. 1993 Apr;13(4):548–554. doi: 10.1161/01.atv.13.4.548. [DOI] [PubMed] [Google Scholar]
  51. Winn E. S., Hu S. P., Hochschwender S. M., Laursen R. A. Studies on the lysine-binding sites of human plasminogen. The effect of ligand structure on the binding of lysine analogs to plasminogen. Eur J Biochem. 1980 Mar;104(2):579–586. doi: 10.1111/j.1432-1033.1980.tb04461.x. [DOI] [PubMed] [Google Scholar]
  52. Wu T. P., Padmanabhan K., Tulinsky A., Mulichak A. M. The refined structure of the epsilon-aminocaproic acid complex of human plasminogen kringle 4. Biochemistry. 1991 Oct 29;30(43):10589–10594. doi: 10.1021/bi00107a030. [DOI] [PubMed] [Google Scholar]
  53. van der Hoek Y. Y., Wittekoek M. E., Beisiegel U., Kastelein J. J., Koschinsky M. L. The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms. Hum Mol Genet. 1993 Apr;2(4):361–366. doi: 10.1093/hmg/2.4.361. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES